Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanggan Qingre Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed by the Xi'an Shangyikang Pharmaceutical Research Institute for the treatment of the common cold and upper respiratory tract infections (URTI). The name "Shanggan" is a Chinese medical abbreviation for upper respiratory infection (shang huxidao ganran), while "Qingre" refers to the "heat-clearing" therapeutic principle in TCM. The drug is administered as an oral liquid and is intended to alleviate symptoms such as fever, headache, and sore throat. It utilizes a synergistic blend of herbal extracts that contain bioactive phytochemicals known for their antipyretic, anti-inflammatory, and antiviral properties, targeting the underlying "heat-toxin" pathology associated with viral respiratory infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shanggan Qingre Oral Liquid.